Biomerica (BMRA) Liabilities and Shareholders Equity (2011 - 2026)

Biomerica has disclosed Liabilities and Shareholders Equity across 16 years of filings, most recently posting $4.9 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $4.9 million, down 33.87% year-over-year; the trailing twelve-month figure through Feb 2026 was $23.7 million (down 25.38% YoY), and the FY2025 annual result was $5.9 million, down 35.76% from the prior year.
• Liabilities and Shareholders Equity came in at $4.9 million for Q1 2026 at Biomerica, down from $6.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $17.6 million in Q1 2022 to a low of $4.9 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $9.3 million (2024), against an average of $9.6 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 31.56% in 2022 and tumbled 53.25% in 2023, its largest moves.
• Biomerica's Liabilities and Shareholders Equity stood at $9.9 million in 2022, then grew by 19.41% to $11.8 million in 2023, then slumped by 38.52% to $7.3 million in 2024, then dropped by 17.05% to $6.0 million in 2025, then slipped by 19.16% to $4.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $4.9 million (Q1 2026), $6.0 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.